People receiving weight-loss drug Wegovy sustained weight loss for up to four years, shedding an average of 10% of their body weight in that time, as per a new study. Wegrovy is a brand that markets semaglutide injections, that have gained widespread attention for their weight-loss effects. The study also found that Semaglutide injections boost an individual's heart health, even when weight loss doesn't take place.

The study, called SELECT, was published in journal Nature Medicine. "At four years, we see ongoing benefits of semaglutide," said Cheng-Han Chen, MD, interventional cardiologist from Cardiologist, who was not involved in the research. Besides the weight loss, it also lead to a loss in cardiovascular outcomes.

The research was conducted on 17000 adults, who had obesity but did not have diabetes. Overall, people who received once-weekly injections of semaglutide lost on average 10.2% of their body weight over the course of four years. All of the study participants continued to lose weight for about 65 weeks, a year and three months, and then their weight remained at a stable level.

Were There Any Side Effects?

What Did The Results Say?

Of the people on the highest dose of Wegovy, 68% lost at least 5% of their body weight. This compared to 21% of people on the placebo. Additionally, of the total people on Wegovy about 23% lost at least 15% of their body weight. For those in the placebo group, only 1.7% lost that much body weight.

Semaglutide Shows Heart Benefits Beyond Weight Loss

Researchers found that even individuals who did not experience significant weight reduction while on the drug saw a reduced risk of major heart events. Recent analysis of the SELECT trial data revealed that semaglutide significantly lowers the risk of heart attack, stroke, and cardiovascular-related deaths in adults with obesity or those who are overweight. Notably, the results of this study lead the US FDA to approve Novo Nordisk's Wegovy for reducing heart-related risks in this group.

What Is Semaglutide?

Are Their Any Side Effects Of Semaglutide?

Semaglutide, marketed under the brand name Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.

Can Chinese medicine cure baldness? Baldness has long been dealt as a matter of shame over health. Products focus on hiding the bald patch rather than curing it. Baldness has in the past made global headlines when South Korean president Lee Jae Myung said 'Baldness is the new enemy' and suggested that insurance should cover the treatment as a part of medical treatment.

Read: South Korean President Says Baldness Is The 'New Enemy'; Wants Insurance To Cover Hair Loss Treatment

Androgenetic alopecia (AGA), better known as pattern hair loss, is the most common form of hair thinning worldwide. While medications like finasteride and minoxidil remain the standard line of treatment, concerns around side effects, lifelong use, and mixed results have led many people to explore gentler, more holistic alternatives.

A new scientific review now suggests that Polygonum multiflorum—a root used in traditional Chinese medicine for over a thousand years—may hold real promise in managing AGA. Historically described as a remedy that can “blacken hair and nourish essence,” the herb is gaining renewed attention as modern research begins to unpack how it actually works at a biological level.

A Multi-Pathway Approach to Hair Health

Most conventional hair-loss treatments target a single biological mechanism. Polygonum multiflorum, however, appears to work on several fronts at once. According to the review, the herb helps reduce the activity of dihydrotestosterone (DHT), a hormone strongly associated with hair follicle shrinkage in AGA.

At the same time, it protects hair follicle cells from premature cell death and activates key growth-related signalling pathways, including Wnt and Sonic Hedgehog (Shh), both crucial for maintaining a healthy hair growth cycle. The herb may also improve scalp blood circulation, potentially enhancing the delivery of oxygen and nutrients to hair follicles—an often overlooked factor in hair thinning.

Ancient Records Meet Modern Biology

“Our analysis bridges ancient wisdom and modern science,” said Han Bixian, the lead author of the review published in the Journal of Holistic Integrative Pharmacy. “What surprised us was how consistently historical texts—from the Tang Dynasty onward—described effects that align closely with today’s understanding of hair biology.”

The researchers examined a wide range of evidence, including laboratory studies, clinical observations, and historical herbal literature. Together, these sources suggest that Polygonum multiflorum does more than simply slow hair loss—it may actively support healthier hair function.

Beyond Slowing Hair Loss

One of the most striking findings is the herb’s potential role in hair regeneration. Rather than only delaying further thinning, Polygonum multiflorum appears to influence multiple growth factors involved in restarting and sustaining the hair cycle. This broader mode of action could give it an edge over treatments that focus on just one biological target.

Safety, Processing, and What Comes Next

The review notes that when properly processed—a critical step in traditional preparation, the herb shows a relatively favorable safety profile. This could make it more appealing to patients concerned about side effects such as sexual dysfunction or scalp irritation commonly linked to existing medications.

That said, the authors stress the need for more high-quality clinical trials to confirm effectiveness, establish safe dosing, and standardize preparation methods. Even so, the findings highlight how rigorous scientific study of traditional remedies can uncover new possibilities for treating common conditions like androgenetic alopecia.

As artificial intelligence becomes a go-to source for quick answers, a new University of Oxford-led study on AI chatbots and medical advice is raising serious concerns about how safe it is to rely on these tools for health guidance.

The research suggests that while AI chatbots can provide medical information, their advice is often inaccurate, inconsistent, and difficult for users to interpret, potentially putting people at risk—especially when dealing with symptoms that need urgent care.

What the Oxford Study Found

The study involved 1,300 participants who were given realistic health scenarios, such as experiencing a severe headache or being a new mother feeling constantly exhausted. Participants were divided into two groups: one group used AI chatbots to understand their symptoms and decide next steps, while the other did not.

Researchers then assessed whether participants correctly identified what might be wrong and whether they made appropriate decisions, such as seeing a GP or visiting A&E.

The results were troubling. People who relied on AI frequently failed to identify the severity of their condition and were often unsure about when to seek professional medical help.

Why Chatbot Advice Can Go Wrong

According to the researchers, one major issue is that people don’t always know what to ask. The study found that chatbot responses varied widely depending on how questions were phrased. Even small changes in wording could lead to completely different answers.

The AI often produced a mix of helpful and misleading information, leaving users to decide which advice mattered. Many participants struggled to distinguish between reliable guidance and unnecessary or confusing details.

As one of the study’s authors explained, when an AI lists multiple possible conditions, users are left guessing which one applies to them—precisely the moment where mistakes can happen.

A Dangerous Gap in Symptom Interpretation

Dr Rebecca Payne, lead medical practitioner on the study, warned that asking chatbots about symptoms could be “dangerous”, particularly when users delay seeking professional care based on AI responses.

Dr Adam Mahdi, the study’s senior author, noted that while AI can share medical facts, people often share information gradually and leave out key details—something chatbots struggle to manage effectively.

Bias, Data, and the Limits of AI

Experts also point out that chatbots are trained on existing medical data, which means they may repeat long-standing biases baked into healthcare systems. As one psychiatry expert put it, a chatbot is only as accurate as human clinicians—and humans are far from perfect.

That said, not everyone is pessimistic.

What Comes Next for AI in Healthcare

Digital health experts argue the technology is evolving. Health-specific versions of general AI chatbots have recently been released by major developers, and these could perform differently in future studies.

The consensus among experts is clear: AI in healthcare should focus on improvement, regulation, and guardrails, not replacement of doctors. Used responsibly, it may support healthcare—but without safeguards, it risks doing more harm than good.

This common pregnancy drug could be linked to cancer. Wes Streeting has been urged to launch a public inquiry into a miscarriage drug called Diethylstilbestrol, which, reports say has "ruined and devastated" the lives of countless women. On Monday, the Health Secretary Streeting met victims of the pregnancy drugs, which has been linked to cancer, early menopause and infertility.

What Is Diethylstilbestrol?

Diethylstilbestrol, commonly known as DES, is a synthetic form of female hormone estrogen, which was prescribed to thousands of pregnant women from 1940 to 1970s.

The drug was used to prevent miscarriage, premature labor and complications of pregnancy. This was also used to suppress breast milk production, as an emergency contraception and to treat symptoms of menopause.

What Is The DES Controversy?

In 1971, Diethylstilbestrol (DES) was linked to a rare cancer of the cervix and vagina known as clear cell adenocarcinoma, prompting US regulators to advise that it should no longer be prescribed to pregnant women. Despite this, the drug continued to be given to expectant mothers across parts of Europe until 1978. DES has also since been associated with other cancers, including breast, pancreatic and cervical cancers, The Telegraph reported.

Campaign group DES Justice UK (DJUK) is now urging Health Secretary Wes Streeting to order a public inquiry and introduce an NHS screening programme to identify people who may have been exposed to the drug before birth.

Victims described DES as “one of the biggest pharmaceutical scandals this country has ever seen,” warning that “the impact of this terrible drug cannot be underestimated as it has ruined and devastated so many lives,” according to The Telegraph.

In November, Streeting acknowledged that the “state got it wrong” and issued an apology to those affected. He also advised anyone who believes they may have been exposed to DES to speak to their GP.

Susie Martin, 55, from Manchester, whose mother was prescribed DES during pregnancy, told The Telegraph she has undergone between 20 and 30 operations as a result of the drug’s effects.

“The impact of this terrible drug cannot be underestimated as it has ruined and devastated so many lives, including my own,” she said. “The physical and emotional pain has been unbearable. I live with a constant fear that I will need more surgery or develop cancer—and I am far from the only one.”

Calling DES a “silent scandal,” Martin said she hopes the government’s engagement will lead to concrete action. “While I welcome Mr Streeting meeting us, it will only matter if he commits to meaningful steps for victims of this shameful chapter in British medical history, including a screening programme and a full statutory public inquiry,” she added.

What Is Happening With The DES Victims?

The Telegraph reported that compensation schemes have been set up for DES victims in the US and Netherlands, however, UK does not have one yet.

"There are harrowing accounts of harm caused by the historic use of Diethylstilbestrol (DES). Some women and their relatives are still suffering from the associated risks of this medicine which have been passed down a generation, and haven’t been supported. The Secretary of State has been looking seriously at this legacy issue and carefully considering what more the government can do to better support women and their families who have been impacted. NHS England has alerted all cancer alliances to this issue so that healthcare professionals are aware of the impacts of DES and the existing NHS screening guidance which sets out the arrangements for those who show signs and symptoms of exposure,” said a Department of Health and Social Care spokesman to The Telegraph.